HomeKYNB • NASDAQ
add
Kyntra Bio Inc
Previous close
$6.78
Day range
$6.75 - $7.35
Year range
$6.32 - $9.70
Market cap
28.73M USD
Avg Volume
39.22K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 1.28M | -59.27% |
Operating expense | 7.25M | -13.13% |
Net income | -14.22M | -179.08% |
Net profit margin | -1.11K | -294.14% |
Earnings per share | -3.51 | -75.50% |
EBITDA | -13.51M | 49.92% |
Effective tax rate | 0.00% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 88.98M | 76.26% |
Total assets | 119.59M | -44.25% |
Total liabilities | 115.12M | -71.09% |
Total equity | 4.48M | — |
Shares outstanding | 4.05M | — |
Price to book | -0.91 | — |
Return on assets | -26.34% | — |
Return on capital | -110.83% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -14.22M | -179.08% |
Cash from operations | -18.33M | 39.84% |
Cash from investing | -51.71M | -3,101.28% |
Cash from financing | -14.00K | -380.00% |
Net change in cash | -70.10M | -143.20% |
Free cash flow | -10.14M | 90.52% |
About
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
Founded
Jan 1, 1993
Headquarters
Website
Employees
34
